ambsadvocate_pumpsndumps / solantey_wcoastguynca:
Irony and sarcasm are super funny. You have been amusing. Now you're just annoying and obsessive. No one here likes Solantey, and Risk has his fair share of enemies. But you are probably on ignore for more people than either of them. I'm adding myself to that list. GBYE!
I would not want to see that. I would be happy to see a partnership for some MANF indication though and that would be your rich uncle scenario without losing control.
.40c by November is a much safer estimate than .40c by end of July. We won't know who our partner is and what the deal is until the end of the summer. 40c before the summer is unlikely, although I wouldn't mind it.
If you are making a plan for this then you are going to set yourself up for disappointment. It is like having a retirement plan that involves spending thousands of dollars on lottery tickets.
I think he let slip that he would be happy with a .50c price target, indirectly. I would be too. More than happy.
Most of what you said is spot on. However...
When you write press releases, that does not guarantee you an article. It doesn't even guarantee you a spot for your press releases. Having a publicity company would help, but that still falls back to your point. I stand firmly by my belief that you'd be hard pressed to get a reputable paper to do a story on LymPro until we have published data. And to your point, even if we could it would not be as useful without a product to sell.
I'm not disagreeing. However, they haven't, which is why there is no story yet. Which is why we should ignore these other stories of other tests, because they don't matter. Once we get our story, nothing else will matter.
Appreciate the actual discourse. I believe you are correct but I also believe that you need something legitimate to tie on to, like new results confirmed by BD or a partnership with Quest. Otherwise for many editors this would feel like a penny stock promotion, and no one will do that if they are a major newspaper.
I fully expect the first piece of news to break to not focus on Amarantus but on the test, its results, BD, Quest, and Cavendish. Obviously Amarantus will be discussed but I doubt it will be the focal point.
It saddens me to think you may not realize you are agreeing with me. Hope many of you pumpers take the LymPro test when it comes to market.
Yes, why wouldn't you?
BD is trusted but.GC hasn't released results yet. I believe he is waiting to maximize the impact (largely because he gave that exact reason months ago). Credibility is very important!
It is easy. As postgost has mentioned, no one believes Amarantus when they release results.
Put yourself in the shoes of a newspaper editor. You can share preliminary positive days that is several years from clinical trials and reports itself as such, and comes from a university, or you can share an incredible story about a test only months from being commercialized by a penny stock with no history of viable products.
Credibility reigns supreme when the press is concerned. If they share news and it causes people to run this stock up and lose money if it turns out GC fleeced them, they have a scandal on their hands, and they will lose readers. No one trusts a penny stock with a fresh CEO. Many legitimate posters and many more sheisters explain why this is a risky investment. Why would a newspaper put their reputation on the line for our company? So some flippers collect a quick buck?
The flip side to this is that once we have the credibility of a partnership, and BDs results, both of which are very close, it will not be hard at all to gain exposure, and this stock will quickly become a momentum stock.
If you try to get your information on what 8-K's mean on a message board you are opening yourself up to some serious trouble. That being said, I did research that anyone is capable of doing (I am not abnormally smart).
The Series D convertible bonds were in relation to some outstanding debt that Dominion agreed to purchase. It only accounts for 1,300 shares at 8%. I believe there were some features for defaulting etc. and because Dominion is heavily invested in Amarantus I believe they were amenable to a change in the terms. This is minor change and limited in scope. It is barely positive.
That's my strategy. If anyone thinks to sell out of the stock entirely in a year though I would heavily advise they keep some skin in the game. If things go well, this could be the next Amgen, and 15,000 shares would be worth $1mil. Obviously the more you hold the more you can earn though! The last thing you'd want to feel is that you sold too early for a stock with this potential.
No matter what you do, keep a minimum of 15,000 shares for 10+ years. If you play it right they will be free and it is a risk worth talking.
There if a book, "How to Win Friends and Influence People" that will only cost you $5. The other made up amount of money? Do whatever you want with it.
I am happy to get an update even if there at no details. However, the phrase I chuckled at was "We have already begun the process of preparing for an orphan drug designation filing with the FDA..." That is the definition of an empty statement.
You are clearly here to amuse yourself and settle a personal vendetta against smitty. So I do not need to tell you that MANF has institutional interest for RP and Wolfram's. I also don't need to tell you they just went to the BIO conference immediately after announcing their most recent partnership with the Snow Foundation. I don't need to tell you to use your brain, because you are intentionally pretending like you are not. No one as obnoxious as you is as dumb as you pretend to be.
Orchestrated. Unfortunately for flippers there is a diminishing pool of fluid shares. This will end with a few making a killing and most getting royally hosed. Those who hold of course get to ride it out just fine.